ENTRY       D10517                      Drug
NAME        Crisantaspase (JAN/INN);
            Enrylaze (TN);
            Erwinase (TN)
FORMULA     C1546H2510N432O476S9
EXACT_MASS  35032.2968
MOL_WEIGHT  35053.6654
SEQUENCE    ADKLPNIVIL ATGGTIAGSA ATGTQTTGYK AGALGVDTLI NAVPEVKKLA NVKGEQFSNM
            ASENMTGDVV LKLSQRVNEL LARDDVDGVV ITHGTDTVEE SAYFLHLTVK SDKPVVFVAA
            MRPATAISAD GPMNLLEAVR VAGDKQSRGR GVMVVLNDRI GSARYITKTN ASTLDTFKAN
            EEGYLGVIIG NRIYYQNRID KLHTTRSVFD VRGLTSLPKV DILYGYQDDP EYLYDAAIQH
            GVKGIVYAGM GAGSVSVRGI AGMRKAMEKG VVVIRSTRTG NGIVPPDEEL PGLVSDSLNP
            AHARILLMLA LTRTSDPKVI QEYFHTY
  TYPE      Peptide
SOURCE      Erwinia chrysanthemi [TAX:556]
REMARK      Therapeutic category: 4291
            ATC code: L01XX02
            Product: D10517<JP>
EFFICACY    Antineoplastic
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01X OTHER ANTINEOPLASTIC AGENTS
                L01XX Other antineoplastic agents
                 L01XX02 Asparaginase
                  D10517  Crisantaspase (JAN/INN) &lt;JP&gt;
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D10517  Crisantaspase (JAN/INN)
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10517
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10517
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10517
DBLINKS     PubChem: 172232610
///
